Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.
Claims database
Disease-modifying therapy
Health economics
Multiple sclerosis
Real-world data
Relapse rate
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
16 Dec 2019
16 Dec 2019
Historique:
received:
20
03
2019
accepted:
19
11
2019
entrez:
18
12
2019
pubmed:
18
12
2019
medline:
19
3
2020
Statut:
epublish
Résumé
In this study, we aimed to understand the trends in total and itemized medical expenses, especially of disease-modifying therapy (DMT), for multiple sclerosis (MS) in Japan through an analysis of health insurance claims data. We analyzed a database containing health insurance claims data from hospitals that have adopted the Diagnosis Procedure Combination/Per-Diem Payment System in Japan. According to an algorithm based on diagnosis codes, data for all patients diagnosed with MS from April 2008 to July 2016 were extracted. Medical costs, rate of each medical treatment, and rate of relapses were analyzed by calendar-year. Medical costs in the month of relapse were compared with average medical costs per month of all MS patients by a cross-sectional analysis. Four thousand three hundred seventy-four MS patients were identified in the database. Total medical cost per patient per month (PPPM) increased from ¥87,640 (US$787.7 or €723.0 as of May 2017) to ¥102,846 (US$924.4 or €848.4) during the study period. This increment was mainly attributed to the growth in cost of outpatient DMT prescriptions, which increased from ¥23,039 (US$207.1 or €190.1) to ¥51,351 (US$461.5 or €423.6). In contrast, the rate of hospitalizations and relapses PPPM decreased during the study period (from 0.053 to 0.030, and 0.032 to 0.019, respectively). Medical costs in the month of relapse (¥424,661, US$3816.8 or €3503.1) were 3.57 times higher than the average monthly costs for all MS patients (¥119,021, US$1069.8 or €981.8), with the majority comprising hospitalization cost. Concomitant with the increased usage of DMT, the total medical cost for treating MS is increasing in Japan. However, rates of relapse and hospitalization have shown a decreasing trend. Although this study does not show the direct causality between DMT and reduction of relapse rates/fewer hospitalizations among MS patients, a reduction in hospital costs has been revealed concomitantly with the increasing prevalence of DMT.
Sections du résumé
BACKGROUND
BACKGROUND
In this study, we aimed to understand the trends in total and itemized medical expenses, especially of disease-modifying therapy (DMT), for multiple sclerosis (MS) in Japan through an analysis of health insurance claims data.
METHODS
METHODS
We analyzed a database containing health insurance claims data from hospitals that have adopted the Diagnosis Procedure Combination/Per-Diem Payment System in Japan. According to an algorithm based on diagnosis codes, data for all patients diagnosed with MS from April 2008 to July 2016 were extracted. Medical costs, rate of each medical treatment, and rate of relapses were analyzed by calendar-year. Medical costs in the month of relapse were compared with average medical costs per month of all MS patients by a cross-sectional analysis.
RESULTS
RESULTS
Four thousand three hundred seventy-four MS patients were identified in the database. Total medical cost per patient per month (PPPM) increased from ¥87,640 (US$787.7 or €723.0 as of May 2017) to ¥102,846 (US$924.4 or €848.4) during the study period. This increment was mainly attributed to the growth in cost of outpatient DMT prescriptions, which increased from ¥23,039 (US$207.1 or €190.1) to ¥51,351 (US$461.5 or €423.6). In contrast, the rate of hospitalizations and relapses PPPM decreased during the study period (from 0.053 to 0.030, and 0.032 to 0.019, respectively). Medical costs in the month of relapse (¥424,661, US$3816.8 or €3503.1) were 3.57 times higher than the average monthly costs for all MS patients (¥119,021, US$1069.8 or €981.8), with the majority comprising hospitalization cost.
CONCLUSION
CONCLUSIONS
Concomitant with the increased usage of DMT, the total medical cost for treating MS is increasing in Japan. However, rates of relapse and hospitalization have shown a decreasing trend. Although this study does not show the direct causality between DMT and reduction of relapse rates/fewer hospitalizations among MS patients, a reduction in hospital costs has been revealed concomitantly with the increasing prevalence of DMT.
Identifiants
pubmed: 31842786
doi: 10.1186/s12883-019-1534-9
pii: 10.1186/s12883-019-1534-9
pmc: PMC6912943
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
324Subventions
Organisme : Takeda Pharmaceutical Company Limited
ID : none
Références
Eur J Neurol. 2016 Jan;23 Suppl 1:18-27
pubmed: 26563094
Mult Scler. 2010 Aug;16(8):956-63
pubmed: 20595246
Neurology. 2014 Sep 9;83(11):1022-4
pubmed: 25200713
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):137-145
pubmed: 27671902
Perspect Medicin Chem. 2014 Oct 05;6:65-72
pubmed: 25336899
Neuroepidemiology. 2016;46(3):209-21
pubmed: 26901651
N Engl J Med. 2006 Mar 2;354(9):942-55
pubmed: 16510748
Mult Scler Relat Disord. 2014 Mar;3(2):147-55
pubmed: 25878002
Am J Manag Care. 2016 Jun;22(6 Suppl):s151-8
pubmed: 27356024
Clin Exp Neuroimmunol. 2016 May;7(2):158-167
pubmed: 27818711
Mult Scler. 2009 Feb;15(2):159-73
pubmed: 18987106
Curr Med Res Opin. 2016 Nov;32(11):1783-1788
pubmed: 27359262
Neurology. 2011 Jul 26;77(4):355-63
pubmed: 21775734
Neurology. 2015 May 26;84(21):2185-92
pubmed: 25911108
Clin Exp Neuroimmunol. 2017 Nov;8(4):318-326
pubmed: 29242717